Amicus Therapeutics (FOLD) News Today $9.59 +0.07 (+0.74%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 44.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,258,208 shares of the biopharmaceNovember 20 at 3:30 AM | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down - Should You Sell?Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down - Here's What HappenedNovember 19 at 2:00 PM | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy RatingStockNews.com upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday.November 16, 2024 | marketbeat.comAvoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics IncNovember 14, 2024 | gurufocus.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLPGSA Capital Partners LLP boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 163.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,800 shares of the biopharmaceuticalNovember 14, 2024 | marketbeat.comAmicus price target raised to $174 from $16 at JPMorganNovember 13, 2024 | markets.businessinsider.comThe Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 ExpertsNovember 13, 2024 | benzinga.comNCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial RightsNovember 12, 2024 | globenewswire.comAmicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $17.00JPMorgan Chase & Co. increased their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday.November 12, 2024 | marketbeat.comBuy Rating on Amicus Therapeutics Driven by Positive Revenue Outlook and Strategic Growth PlansNovember 10, 2024 | markets.businessinsider.comFiera Capital Corp Has $34.31 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Fiera Capital Corp cut its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 39.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,212,561 shares of the biopharmaceutical company's stock afteNovember 9, 2024 | marketbeat.comBradley L. Campbell Sells 7,901 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) StockNovember 8, 2024 | insidertrades.comAmicus Therapeutics (NASDAQ:FOLD) Cut to "Hold" at StockNews.comStockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday.November 8, 2024 | marketbeat.comAmicus Therapeutics Reports Strong Q3 2024 GrowthNovember 8, 2024 | markets.businessinsider.comAmicus Therapeutics (NASDAQ:FOLD) Stock, Short Interest ReportNovember 8, 2024 | benzinga.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS), Amicus (FOLD) and Janux Therapeutics Inc (JANX)November 7, 2024 | markets.businessinsider.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comAmicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at GuggenheimGuggenheim boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday.November 7, 2024 | marketbeat.comAmicus Therapeutics' (FOLD) "Hold" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday.November 7, 2024 | marketbeat.comAmicus Therapeutics: Strong Financial Performance and Growth Prospects Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comAmicus (FOLD) Gets a Hold from NeedhamNovember 7, 2024 | markets.businessinsider.comAmicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 7, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comOld West Investment Management LLC Acquires 292,976 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Old West Investment Management LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 617.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 340,441 shares of the biopharmaceutical company's stocNovember 6, 2024 | marketbeat.comBradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) StockNovember 5, 2024 | insidertrades.comAmicus Therapeutics (NASDAQ:FOLD) Stock, Option ChainNovember 2, 2024 | benzinga.comAmicus Therapeutics to Present at Upcoming Investor Conferences in November 2024November 1, 2024 | globenewswire.comabrdn plc Raises Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)abrdn plc boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 9.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,808,792 shares of the biopharmaceutical company's stock after buying anNovember 1, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.comStockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday.October 31, 2024 | marketbeat.comAmicus Therapeutics (FOLD) Scheduled to Post Earnings on WednesdayAmicus Therapeutics (NASDAQ:FOLD) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=640812)October 30, 2024 | marketbeat.com105,868 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Semanteon Capital Management LPSemanteon Capital Management LP acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 105,868 shares of the biopharmaceutical comOctober 28, 2024 | marketbeat.comAmicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024October 28, 2024 | globenewswire.comAssenagon Asset Management S.A. Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Assenagon Asset Management S.A. increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 141.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,037,896 shares of the biopharmaceutical company'sOctober 26, 2024 | marketbeat.comAmicus (FOLD) Gets a Buy from TD CowenOctober 23, 2024 | markets.businessinsider.comAmicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to BuyStockNews.com raised Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Wednesday.October 23, 2024 | marketbeat.comAmicus Therapeutics: Long-term Growth Secured by Strategic Patent Expansion and Market PositioningOctober 23, 2024 | markets.businessinsider.comAmerican Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseasOctober 21, 2024 | globenewswire.comAmicus Therapeutics IncOctober 19, 2024 | money.usnews.comAmicus: Teva Settlement Clears Revenue Path Forward For GalafoldOctober 18, 2024 | seekingalpha.comZacks Research Issues Optimistic Outlook for FOLD EarningsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Research analysts at Zacks Research raised their Q3 2025 earnings estimates for Amicus Therapeutics in a research note issued to investors on Wednesday, October 16th. Zacks Research analyst R. Department now forecasts that the biopharmaceutiOctober 18, 2024 | marketbeat.comAmicus Therapeutics Settles Galafold Patent Litigation With TevaOctober 17, 2024 | markets.businessinsider.comAmicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Bank of AmericaBank of America raised their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a report on Thursday.October 17, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up - Here's WhyAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up - Should You Buy?October 17, 2024 | marketbeat.comAmicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder DrugOctober 17, 2024 | benzinga.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q2 2025 Earnings of $0.01 Per Share, Zacks Research ForecastsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Investment analysts at Zacks Research issued their Q2 2025 EPS estimates for shares of Amicus Therapeutics in a report released on Wednesday, October 16th. Zacks Research analyst R. Department forecasts that the biopharmaceutical company wilOctober 17, 2024 | marketbeat.comAmicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with TevaOctober 17, 2024 | globenewswire.comSG Americas Securities LLC Invests $554,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD)SG Americas Securities LLC purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 51,908 shares of the biopharmaceuticalOctober 16, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Cut to Hold at StockNews.comStockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday.October 15, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) PT Lowered to $18.00 at Morgan StanleyMorgan Stanley cut their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating for the company in a report on Friday.October 11, 2024 | marketbeat.comAmicus Therapeutics Inc (FOLD) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...October 9, 2024 | finance.yahoo.com Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼0.660.45▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼54▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BHC News ARWR News PRGO News BBIO News BHVN News ALLK News BPMC News EXEL News EXAS News RGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FOLD Stock Alerts